University of Bern

NASA Welcomes Switzerland as Newest Artemis Accords Signatory

Retrieved on: 
Monday, April 15, 2024
Use, Agreement, University, Outer Space Treaty, Exploration, Earth science, University of Bern, Economy, Education, State, Artemis Accords, NASA, Innovation, ESA, Partnership, NASA Headquarters, European Space Agency, Rescue, Planetary science, Multimedia, United, Artemis, Celestial, Registration Convention

"Today, we marked a giant leap forward in the partnership between the United States and Switzerland," said NASA Administrator Bill Nelson.

Key Points: 
  • "Today, we marked a giant leap forward in the partnership between the United States and Switzerland," said NASA Administrator Bill Nelson.
  • "As we welcome you into the Artemis Accords family, we expand our commitment to explore the unknown openly and peacefully.
  • "With the signature of the Artemis Accords we renew our commitment to jointly explore the heavens above us."
  • For more information on the Artemis Accords, visit:
    View original content to download multimedia: https://www.prnewswire.com/news-releases/nasa-welcomes-switzerland-as-ne...

MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, MAIA, Gilead Sciences, Medicine, ASH, ASCO, SAB, FDA, Drug development, AbbVie, European Hematology Association, Mantle cell lymphoma, Pleasure, Kite Pharma, Hematology, EHA, University, Society, University of Bern, Patient, NK, Pharmacyclics, Acute lymphoblastic leukemia, Publication, Research, Cancer, Pharmaceutical industry

CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).

Key Points: 
  • CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).
  • Dr. Vezan currently serves as Vice President, Global Clinical Development at BeiGene.
  • Vezan holds vast experience in guiding oncology assets through all stages of development, from research to clinical strategies and registration.
  • Dr. Remus Vezan commented, “It is my pleasure and privilege to join MAIA as scientific advisor and support the efforts of the MAIA team in advancing the clinical development of its first-in-class telomere targeting agent.

International science organizations sign agreement to provide hardware for the Deep Underground Neutrino Experiment

Retrieved on: 
Wednesday, December 6, 2023
Proton, State University of Campinas, Partnership, CERN, Soil, Particle physics, DUNE, Acquisition, Research, Physics, Electronics, University, Behavior, DOE, IN2P3, SURF, INFN, Student, Engineering, University of Bern, Calibration, Deep Underground Neutrino Experiment, Renewable energy

Batavia, Illinois, Dec. 06, 2023 (GLOBE NEWSWIRE) -- The Deep Underground Neutrino Experiment — also known as DUNE — is an international mega science experiment that will use enormous particle detectors to study the behavior of neutrinos, which might indicate why we live in a matter-dominated universe.

Key Points: 
  • Batavia, Illinois, Dec. 06, 2023 (GLOBE NEWSWIRE) -- The Deep Underground Neutrino Experiment — also known as DUNE — is an international mega science experiment that will use enormous particle detectors to study the behavior of neutrinos, which might indicate why we live in a matter-dominated universe.
  • “DUNE will help answer some of the biggest questions in the universe and has the potential to transform the field of neutrino physics.
  • Notably, CERN’s commitment to LBNF and DUNE represents its first investment in infrastructure for a physics experiment outside of Europe.
  • To pursue these science goals, DUNE will study neutrino oscillation, a phenomenon in which a neutrino’s property, called flavor, changes as it travels.

Carina Biotech Appoints Two New U.S. Based Biotechnology Executives to the Board of Directors

Retrieved on: 
Monday, June 5, 2023
CLL, Gaucher's disease, Medicine, University, Chronic lymphocytic leukemia, SLL, Acute lymphoblastic leukemia, Biotechnology, Food, Food and Drug Administration, MBA, Providence College, University of Bern, Pharmacyclics, Audit committee, Waldenström macroglobulinemia, Genzyme, Patient, Mantle cell lymphoma, Hyperphosphatemia, Cero, Bone marrow, Kite Pharma, Fabry disease, FDA, Therapy, Suffolk University, Imiglucerase, IND, Sevelamer, Safety, Pharmaceutical industry, Ibrutinib

ADELAIDE, Australia, June 05, 2023 (GLOBE NEWSWIRE) -- Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced the appointment of Michael S. Wyzga, M.B.A., and Remus Vezan M.D., Ph.D., to its Board of Directors.

Key Points: 
  • ADELAIDE, Australia, June 05, 2023 (GLOBE NEWSWIRE) -- Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced the appointment of Michael S. Wyzga, M.B.A., and Remus Vezan M.D., Ph.D., to its Board of Directors.
  • Mr. Wyzga is an accomplished biotechnology executive who brings to Carina’s Board over two decades of expertise as a leader and advisor to life sciences companies.
  • “We are delighted to welcome two seasoned executives that bring a wealth of expertise in the U.S. biotechnology industry as independent Directors to the Carina Board,” remarked Leanna Read, Ph.D., Chair of Carina’s Board of Directors.
  • Their insight and contribution have been invaluable.”
    Mr. Gosling will continue to support Carina on the Governance, People and Remuneration Committee, whilst Mr. Latham will remain Company Secretary.

Web3 Foundation Appoints Chief Financial Officer to Strengthen the Executive Management

Retrieved on: 
Wednesday, March 1, 2023
Technology, Blockchain, Das Kapital, Ecosystem, Digital asset, Liquidity, University, MBA, CFA, Polka dot, Lucerne University of Applied Sciences and Arts, Business administration, Applied science, Web3, How I Braved Anu Aunty and Co-Founded a Million Dollar Company, Growth, Venture capital, CFO, The arts, University of Bern, Cryptocurrency, Management

Today, Web3 Foundation , whose flagship project is the Polkadot blockchain protocol , announces the appointment of Thomas Fecker Boxler as Chief Financial Officer (CFO) and member of the Executive Management Team with effect from 1 March 2023.

Key Points: 
  • Today, Web3 Foundation , whose flagship project is the Polkadot blockchain protocol , announces the appointment of Thomas Fecker Boxler as Chief Financial Officer (CFO) and member of the Executive Management Team with effect from 1 March 2023.
  • As the Web3 Foundation’s CFO, Thomas will assume the oversight and the book of work of the Foundation’s finance and operational activities.
  • He will directly report to Bertrand Perez, Chief Executive Officer.
  • Thomas also served as the Chief Operating Officer and Chief Financial Officer at Stone Milliner Asset Management and Kraus Partner Investment Solutions.

THE PROSTATE CANCER FOUNDATION ANNOUNCES 2022 CHALLENGE AWARDS TOTALING MORE THAN $12 MILLION FOR PROSTATE CANCER RESEARCH

Retrieved on: 
Tuesday, January 31, 2023
Metastasis, Methylation, Rate, University of Pennsylvania, Incidence, Biomarker, University, University of Connecticut, MPH, Veterans Health Administration, Massachusetts General Hospital, Doctor of Science, Johns Hopkins University, Dana–Farber Cancer Institute, Veteran, Harvard T.H. Chan School of Public Health, Prostate, ETH Zurich, Machine learning, University of Bern, Prostate cancer, Ponce Health Sciences University, Roswell Park Comprehensive Cancer Center, PCF, Prostate Cancer Foundation, Roswell Park, University of California, Duke University, Harvard University, Public health, RNA, Research, Memorial Sloan Kettering Cancer Center, Oregon Health & Science University, University of Cambridge, MD Anderson Cancer Center, Aggression, University of Chicago, Public, Pharmaceutical industry, Vaccine, Management, MD, PCA, Doctor of Philosophy

LOS ANGELES, Jan. 31, 2023 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2022 Class of PCF Team Challenge Award recipients and a total of more than $12 million in funding for innovative prostate cancer research.

Key Points: 
  • LOS ANGELES, Jan. 31, 2023 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the 2022 Class of PCF Team Challenge Award recipients and a total of more than $12 million in funding for innovative prostate cancer research.
  • PCF Challenge Awards fund international, multi-institutional, cross-disciplinary teams of investigators conducting highly innovative research with the greatest potential for accelerating new and improved treatments for advanced prostate cancer.
  • Following a rigorous peer review process that assessed each project's scientific merit and potential patient impact, 15 highly coveted PCF Challenge Awards totaling more than $12 million were granted to teams at some of the world's leading cancer research institutions.
  • (Demonstrating the mechanisms and potential for NLRP3-activation as a new immunotherapeutic strategy, alone or in combination with androgen deprivation therapy and/or checkpoint immunotherapy.)

AGCO Agriculture Foundation Launches a Three-Year Project with Bern University of Applied Sciences

Retrieved on: 
Monday, October 10, 2022
Agriculture, Natural Resources, Sustainability, Environment, University, Philanthropy, Education, Foundation, Food science, Efficiency, School, Agriculture, Chairperson, University of Bern, NYSE, Soil, Farmer, Food security, Twitter, AAF, CHF, Technology, University, Bern University of Applied Sciences, AGCO, Hunger, Applied science, Precision, Renewable energy, Central Europe

The AGCO Agriculture Foundation (AAF) , a private foundation with the vision to prevent and relieve hunger through sustainable agricultural development, today announced a CHF 195,000 donation to Bern University of Applied Sciences (School of Agricultural, Forest and Food Sciences).

Key Points: 
  • The AGCO Agriculture Foundation (AAF) , a private foundation with the vision to prevent and relieve hunger through sustainable agricultural development, today announced a CHF 195,000 donation to Bern University of Applied Sciences (School of Agricultural, Forest and Food Sciences).
  • The project work will be completed within the framework of University students' engagement to complete master's and bachelor's theses on the project's focus and other related sustainability issues.
  • Together with the Bern University of Applied Sciences (School of Agricultural, Forest and Food Sciences) and technical support from the AGCO Swiss Future Farm , the project will promote the use of precision-planted arable crops in rows as a substitute, making more areas available.
  • The AGCO Agriculture Foundation (AAF), initiated by AGCO Corporation (NYSE: AGCO) in 2018, is a private foundation with the vision to prevent and relieve hunger.

Ultivue and ngTMA® Announce Collaborative Agreement to Provide Multiplex and Spatial Analysis for Clinical Research

Retrieved on: 
Thursday, September 29, 2022
Software, General Health, Pharmaceutical, Oncology, Data Management, Medical Devices, Technology, Clinical Trials, Science, Biotechnology, Other Science, Health, Institute, Precision medicine, Corporation, Histology, Doctor of Philosophy, Armed Forces Institute of Pathology, TMA, Quality control, MIF, Industry, Noise, Solution, Documentation, Tumor microenvironment, Research, University of Bern, University, TRU, Medical imaging, Pathology

Ultivue develops unique solutions for use in mIF applications, imaging, and spatial phenomics.

Key Points: 
  • Ultivue develops unique solutions for use in mIF applications, imaging, and spatial phenomics.
  • ngTMA supports research collaborators with an interdisciplinary approach to studying tumor biology and disease states.
  • We are thrilled to be partnering with ngTMA to jointly empower biopharma customers with tissue multiplex services.
  • Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology.

CytoImmune Therapeutics Appoints Remus Vezan, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Wednesday, September 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cero, University, Lymphatic system, Program, NK, Large-cell lung carcinoma, Therapy, CAR, Food and Drug Administration, Engineering, Pharmacyclics, Multiple myeloma, Medicine, Food, Acute myeloid leukemia, Mantle cell lymphoma, Acute lymphoblastic leukemia, Leadership, Immune system, FDA, University of Bern, Adult, Industry, Patient, Waldenström's macroglobulinemia, Pharmaceutical industry, Vaccine, Medical imaging

CytoImmune Therapeutics, a clinical-stage immuno-oncology company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, today announced the appointment of Remus Vezan, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • CytoImmune Therapeutics, a clinical-stage immuno-oncology company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, today announced the appointment of Remus Vezan, M.D., Ph.D., as Chief Medical Officer.
  • Remus brings an ideal combination of expertise to CytoImmune, having led the successful implementation and execution of clinical development strategies for several biopharmaceutical companies focused on both immuno-oncology and cell therapies, said Christina Coughlin, M.D., Ph.D., Chief Executive Officer of CytoImmune.
  • I am pleased to join the team at this exciting time in the evolution of the company.
  • Dr. Vezan joins CytoImmune from CERo Therapeutics where he served as Chief Medical Officer.

PHYLEX BIOSCIENCES PUBLISHES POSITIVE RESULTS OF PROTECTION STUDY AGAINST SARS-CoV-2 DELTA VARIANT WITH ITS SECOND-GENERATION mRNA VACCINE

Retrieved on: 
Wednesday, March 23, 2022
Pasteur Institute of India, Population, Korea Disease Control and Prevention Agency, CDC, Coronavirus, Vaccine, Genomics, Respiratory tract, Pasteur Institute, CEO, Severe acute respiratory syndrome coronavirus 2, Omicron, Preprint, Immunology, Technology, RNA transfection, COVID-19, Institute, Center, University of Bern, DEL, Pascal Brandys, University, Infection, Antibody, Virology

The current vaccines offer limited protection over time against the omicron variant that is now dominating worldwide and likely less protection against future variants of concern.

Key Points: 
  • The current vaccines offer limited protection over time against the omicron variant that is now dominating worldwide and likely less protection against future variants of concern.
  • Phylex BioSciences has published the preprint of a research article ( https://www.biorxiv.org/content/10.1101/2022.03.21.485224v1 ) on the results of immunogenicity and protection studies of its novel mRNA vaccine.
  • The mRNA vaccine encodes for a nanoparticle displaying 60 copies of the antigen based upon the receptor binding domain of the delta variant.
  • In virus neutralization assays neutralization titers of Phylex vaccine-elicited sera against the SARS-CoV-2 delta variant were up to 32-fold as compared with current mRNA vaccine-elicited sera.